Risk of Bleeding in Patients Undergoing Coronar...

By HEOR Staff Writer

July 20, 2023

Dual antiplatelet therapy, a combination of aspirin and clopidogrel, prasugrel or ticagrelor, is recommended for up to 12 months for secondary prevention of ischemic events among people undergoing coronary intervent...
New Hope for Sickle Cell Disease: Groundbreaking Gene Therapies Under Review
Unlocking the Economic Potential of Dementia Research: A Call for Increased I...
Breaking Down the Financial Burden of Health Expenses in India
Revolutionising Oncology Medicine: A Precision Approach that Cuts Costs and B...
The Power of Pharmacist Interventions in Improving Glycemic Control for Diabe...
Lessons for Specialty Care Payment Reforms: Insights from Maryland’s GB...
Alarming Rise in Breast and Cervical Cancers in Low- and Middle-Income Countr...
Revolutionizing Healthcare in Australia and New Zealand: Strengthening Medica...
CMS sheds light on the future of medical schemes and NHI in South Africa
Public Procurement of Medicines in Europe: Key Findings and Best Practices 
Assessing and Implementing Digital Health Solutions: Challenges and Opportuni...
New treatment option for active lupus nephritis!